These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

752 related items for PubMed ID: 27308830

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.
    Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI.
    Breast Cancer Res Treat; 2006 Jun; 97(3):263-74. PubMed ID: 16333527
    [Abstract] [Full Text] [Related]

  • 7. Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.
    Giannoudis A, Malki MI, Rudraraju B, Mohhamed H, Menon S, Liloglou T, Ali S, Carroll JS, Palmieri C.
    Breast Cancer Res; 2020 Nov 16; 22(1):126. PubMed ID: 33198803
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
    Simigdala N, Gao Q, Pancholi S, Roberg-Larsen H, Zvelebil M, Ribas R, Folkerd E, Thompson A, Bhamra A, Dowsett M, Martin LA.
    Breast Cancer Res; 2016 Jun 01; 18(1):58. PubMed ID: 27246191
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer.
    Liu S, Meng X, Chen H, Liu W, Miller T, Murph M, Lu Y, Zhang F, Gagea M, Arteaga CL, Mills GB, Meric-Bernstam F, González-Angulo AM.
    Oncotarget; 2014 Oct 15; 5(19):9049-64. PubMed ID: 24979294
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
    Martin LA, Pancholi S, Farmer I, Guest S, Ribas R, Weigel MT, Thornhill AM, Ghazoui Z, A'Hern R, Evans DB, Lane HA, Johnston SR, Dowsett M.
    Breast Cancer Res; 2012 Oct 17; 14(5):R132. PubMed ID: 23075476
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2.
    Pancholi S, Lykkesfeldt AE, Hilmi C, Banerjee S, Leary A, Drury S, Johnston S, Dowsett M, Martin LA.
    Endocr Relat Cancer; 2008 Dec 17; 15(4):985-1002. PubMed ID: 18824559
    [Abstract] [Full Text] [Related]

  • 16. Significance of ER-Src axis in hormonal therapy resistance.
    Vallabhaneni S, Nair BC, Cortez V, Challa R, Chakravarty D, Tekmal RR, Vadlamudi RK.
    Breast Cancer Res Treat; 2011 Nov 17; 130(2):377-85. PubMed ID: 21184269
    [Abstract] [Full Text] [Related]

  • 17. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
    Fu X, Creighton CJ, Biswal NC, Kumar V, Shea M, Herrera S, Contreras A, Gutierrez C, Wang T, Nanda S, Giuliano M, Morrison G, Nardone A, Karlin KL, Westbrook TF, Heiser LM, Anur P, Spellman P, Guichard SM, Smith PD, Davies BR, Klinowska T, Lee AV, Mills GB, Rimawi MF, Hilsenbeck SG, Gray JW, Joshi A, Osborne CK, Schiff R.
    Breast Cancer Res; 2014 Sep 11; 16(5):430. PubMed ID: 25212826
    [Abstract] [Full Text] [Related]

  • 18. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J, Liu M, Yang L, Tu G, Zhu Q, Chen M, Cheng H, Luo H, Fu W, Li Z, Yang G.
    Breast Cancer Res; 2015 May 21; 17(1):69. PubMed ID: 25990368
    [Abstract] [Full Text] [Related]

  • 19. Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers.
    Ribas R, Ghazoui Z, Gao Q, Pancholi S, Rani A, Dunbier A, Dowsett M, Martin LA.
    Breast Cancer Res; 2014 Oct 31; 16(5):447. PubMed ID: 25358600
    [Abstract] [Full Text] [Related]

  • 20. Downregulation of Choline Kinase-Alpha Enhances Autophagy in Tamoxifen-Resistant Breast Cancer Cells.
    Kim HS, Tian L, Jung M, Choi SK, Sun Y, Kim H, Moon WK.
    PLoS One; 2015 Oct 31; 10(10):e0141110. PubMed ID: 26496360
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.